UAP56 is an important mediator of Angiotensin II/platelet derived growth factor induced vascular smooth muscle cell DNA synthesis and proliferation

Biochemical and Biophysical Research Communications

Volumn 431, Issue 3, 2013, Pages 636-640

  Sahni, Abha ^a,b   Wang, Nadan ^a,c   Alexis, Jeffrey ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

DNA synthesis; Helicase; Proliferation; UAP56

Indexed keywords

ANGIOTENSIN II; BREAKPOINT CLUSTER REGION PROTEIN; CELL PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN UAP56; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; CAROTID ARTERY; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DEAD-BOX RNA HELICASES; DNA; DNA REPLICATION; E2F TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; MICE; MICE, INBRED STRAINS; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; RATS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84873711105     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.014     Document Type: Article

References (27)

1. Bunkenburg B., van Amelsvoort T., Rogg H., Wood J.M. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992, 20:746-754.
2. Fujita N., Furukawa Y., Itabashi N., Okada K., Saito T., Ishibashi S. Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H204-H212.
3. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension 1992, 20:713-736.
4. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J. Clin. Invest. 1989, 83:1419-1424.
5. Alexis J.D., Wang N., Che W., Lerner-Marmarosh N., Sahni A., Korshunov V.A., et al. Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells. Circ. Res. 2009, 104:69-78.
6. Sahni, N. Wang, J.D. Alexis, UAP56 is a novel interacting partner of Bcr in regulating vascular smooth muscle cell DNA synthesis. Biochem. Biophys. Res. Commun. 420 (2012) 511-515.
7. Shen J., Zhang L., Zhao R. Biochemical characterization of the ATPase and helicase activity of UAP56, an essential pre-mRNA splicing and mRNA export factor. J. Biol. Chem. 2007, 282:22544-22550.
8. Gatfield D., Le Hir H., Schmitt C., Braun I.C., Kocher T., Wilm M., et al. The DExH/D box protein HEL/UAP56 is essential for mRNA nuclear export in Drosophila. Curr. Biol. 2001, 11:1716-1721.
9. Kota K.P., Wagner S.R., Huerta E., Underwood J.M., Nickerson J.A. Binding of ATP to UAP56 is necessary for mRNA export. J. Cell Sci. 2008, 121:1526-1537.
10. Shen H., Zheng X., Shen J., Zhang L., Zhao R., Green M.R. Distinct activities of the DExD/H-box splicing factor hUAP56 facilitate stepwise assembly of the spliceosome. Genes Dev. 2008, 22:1796-1803.
11. T. Yamazaki, N. Fujiwara, H. Yukinaga, M. Ebisuya, T. Shiki, T. Kurihara, et al. The closely related RNA helicases, UAP56 and URH49, preferentially form distinct mRNA export machineries and coordinately regulate mitotic progression. Mol. Biol. Cell 21 (2010) 2953-2965.
12. Duff J.L., Marrero M.B., Paxton W.G., Charles C.H., Lau L.F., Bernstein K.E., et al. Angiotensin II induces 3CH134, a protein-tyrosine phosphatase, in vascular smooth muscle cells. J. Biol. Chem. 1993, 268:26037-26040.
13. Sahni A., Wang N., Alexis J.D. UAP56 is an important regulator of protein synthesis and growth in cardiomyocytes. Biochem. Biophys. Res. Commun. 2010, 393:106-110.
14. Abe J., Zhou W., Takuwa N., Taguchi J., Kurokawa K., Kumada M., et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. 1994, 54:3407-3412.
15. Korshunov V.A., Berk B.C. Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2185-2191.
16. Attwooll C., Lazzerini Denchi E., Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004, 23:4709-4716.
17. Chen H.Z., Tsai S.Y., Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 2009, 9:785-797.
18. Fuller-Pace F.V. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 2006, 34:4206-4215.
19. Rocak S., Linder P. DEAD-box proteins: the driving forces behind RNA metabolism. Nat. Rev. Mol. Cell Biol. 2004, 5:232-241.
20. Akao Y., Marukawa O., Morikawa H., Nakao K., Kamei M., Hachiya T., et al. The rck/p54 candidate proto-oncogene product is a 54-kilodalton D-E-A-D box protein differentially expressed in human and mouse tissues. Cancer Res. 1995, 55:3444-3449.
21. Yang L., Lin C., Liu Z.R. Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Mol. Cancer Res. 2005, 3:355-363.
22. Yang L., Lin C., Zhao S., Wang H., Liu Z.R. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J. Biol. Chem. 2007, 282:16811-16819.
23. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 2002, 16:245-256.
24. Ehsan A., Mann M.J., Dell'Acqua G., Dzau V.J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J. Thorac. Cardiovasc. Surg. 2001, 121:714-722.
25. Miyake T., Aoki M., Morishita R. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model. Cardiovasc. Res. 2008, 79:706-714.
26. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakama M., Zhang L., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:5855-5859.
27. Bracken A.P., Ciro M., Cocito A., Helin K. E2F target genes: unraveling the biology. Trends Biochem. Sci. 2004, 29:409-417.